A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Share this content:
A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Sponsor and Collaborators
Roswell Park Cancer Institute
Novartis

Contact
AskRPCI 1-877-275-7724
AskRPCI@roswellpark.org

Principal Investigator
Roberto Pili, MD
Roswell Park Cancer Institute

ClinicalTrials.gov Identifier
NCT01037257
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters